Clinical significance of serum tenascin-C levels in breast cancer

Tumor Biology

Volumn 35, Issue 7, 2014, Pages 6619-6625

  Tastekin, D ^a   Tas, F ^a   Karabulut, S ^a   Duranyildiz, D ^a   Serilmez, M ^a   Guveli, M ^a   Vatansever, S ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Breast cancer; Prognosis; Tenascin C

Indexed keywords

ANTINEOPLASTIC AGENT; CA 15-3 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; LACTATE DEHYDROGENASE; PROGESTERONE RECEPTOR; TENASCIN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; TENASCIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84905007303     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1875-3     Document Type: Article

References (27)

1. Midwood KS, Hussenet T, Langlois B, Orend G. Advances in tenascin-C biology. Cell Mol Life Sci. 2011;68(19):3175-99.
2. Kusagawa H, Onoda K, Namikawa S, Yada I, Okada A, Yoshida T, et al. Expression and degeneration of tenascin-C in human lung cancers. Br J Cancer. 1998;77(1):98-102. (Pubitemid 28029779)
3. Leins A, Riva P, Lindstedt R, Davidoff MS, Mehraein P, Weis S. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma. Cancer. 2003;98(11):2430-9. (Pubitemid 37466658)
4. Jahkola T, Toivonen T, Virtanen I, von Smitten K, Nordling S, von Boguslawski K, et al. Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence. Br J Cancer. 1998;78(11):1507-13. (Pubitemid 28517549)
5. Orend G, Chiquet-Ehrismann R. Tenascin-C induced signaling in cancer. Cancer Lett. 2006;244(2):143-63. (Pubitemid 44508708)
6. Orend G. Potential oncogenic action of tenascin-C in tumorigenesis. Int J Biochem Cell Biol. 2005;37(5):1066-83. (Pubitemid 40311747)
7. Oskarsson T, Acharyya S, Zhang XH, Vanharanta S, Tavazoie SF, Morris PG, et al. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med. 2011;17(7): 867-74.
8. Guttery DS, Shaw JA, Lloyd K, Pringle JH, Walker RA. Expression of tenascin-C and its isoforms in the breast. Cancer Metastasis Rev. 2010;29(4):595-606.
9. Ferguson JE, Schor AM, Howell A, Ferguson MW. Tenascin distribution in the normal human breast is altered during the menstrual cycle and in carcinoma. Differentiation. 1990;42(3):199-207. (Pubitemid 20104081)
10. Howeedy AA, Virtanen I, Laitinen L, Gould NS, Koukoulis GK, Gould VE. Differential distribution of tenascin in the normal, hyperplastic, and neoplastic breast. Lab Investig. 1990;63(6):798-806.
11. Gould VE, Koukoulis GK, Virtanen I. Extracellular matrix proteins and their receptors in the normal, hyperplastic and neoplastic breast. Cell Differ Dev. 1990;32(3):409-16.
12. Jahkola T, Toivonen T, Nordling S, von Smitten K, Virtanen I. Expression of tenascin-C in intraductal carcinoma of human breast: relationship to invasion. Eur J Cancer. 1998;34(11):1687-92. (Pubitemid 28474220)
13. Goepel C, Buchmann J, Schultka R, Koelbl H. Tenascin-A marker for the malignant potential of preinvasive breast cancers. Gynecol Oncol. 2000;79(3):372-8.
14. Ishihara A, Yoshida T, Tamaki H, Sakakura T. Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance. Clin Cancer Res. 1995;1(9):1035-41.
15. Jahkola T, Toivonen T, von Smitten K, Blomqvist C, Virtanen I. Expression of tenascin in invasion border of early breast cancer correlates with higher risk of distant metastasis. Int J Cancer. 1996;69(6):445-7. (Pubitemid 27050519)
16. Shoji T, Kamiya T, Tsubura A, Hamada Y, Hatano T, Hioki K, et al. Tenascin staining positivity and the survival of patients with invasive breast carcinoma. J Surg Res. 1993;55(3):295-7. (Pubitemid 23346864)
17. Ioachim E, Charchanti A, Briasoulis E, Karavasilis V, Tsanou H, Arvanitis DL, et al. Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur J Cancer. 2002;38(18):2362-70. (Pubitemid 35387487)
18. Suwiwat S, Ricciardelli C, Tammi R, Tammi M, Auvinen P, Kosma VM, et al. Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin Cancer Res. 2004;10(7):2491-8. (Pubitemid 38445711)
19. Helleman J, Jansen MP, Ruigrok-Ritstier K, van Staveren IL, Look MP, Meijer-van Gelder ME, et al. Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response. Clin Cancer Res. 2008;14(17):5555-64.
20. Iskaros BF, Hu X, Sparano JA, Fineberg SA. Tenascin pattern of expression and established prognostic factors in invasive breast carcinoma. J Surg Oncol. 1998;68(2):107-12. (Pubitemid 28269979)
21. Tökés AM, Hortoványi E, Csordás G, Kulka J, Mózes G, Hatalyák A, et al. Immunohistochemical localisation of tenascin in invasive ductal carcinoma of the breast. Anticancer Res. 1999;19(1A):175-9. (Pubitemid 29168235)
22. Moch H, Torhorst J, Dürmüller U, Feichter GE, Sauter G, Gudat F. Comparative analysis of the expression of tenascin and established prognostic factors in human breast cancer. Pathol Res Pract. 1993;189(5):510-4. (Pubitemid 23220483)
23. Ishiwata T, Takahashi K, Shimanuki Y, Ohashi R, Cui R, Takahashi F, et al. Serum tenascin-C as a potential predictive marker of angiogenesis in non-small cell lung cancer. Anticancer Res. 2005;25(1B): 489-95. (Pubitemid 40470055)
24. Burchardt ER, Hein R, Bosserhoff AK. Laminin, hyaluronan, tenascin-C and type VI collagen levels in sera from patients with malignant melanoma. Clin Exp Dermatol. 2003;28(5):515-20. (Pubitemid 37100556)
25. Pauli C, Stieber P, Schmitt UM, Andratschke M, Hoffmann K, Wollenberg B. The significance of Tenascin-C serum level as tumor marker in squamous cell carcinoma of the head and neck. Anticancer Res. 2002;22(5):3093-7.
26. Riedl S, Bodenmüller H, Hinz U, Holle R, Möller P, Schlag P, et al. Significance of tenascin serum level as tumor marker in primary colorectal carcinoma. Int J Cancer. 1995;64(1):65-9.
27. Degen M, Brellier F, Schenk S, Driscoll R, Zaman K, Stupp R, et al. Tenascin-W, a new marker of cancer stroma, is elevated in sera of colon and breast cancer patients. Int J Cancer. 2008;122(11): 2454-61. (Pubitemid 351590477)